Pemetor 100 mg (Pemetrexed) Injection: Advanced Therapy for NSCLC and Mesothelioma
Introduction
Pemetor 100 mg Injection represents a significant advancement in targeted cancer therapy, delivering the multi-targeted antifolate agent pemetrexed in a professionally formulated injectable solution. This premium oncology medication, manufactured by Eskayef Pharmaceuticals Ltd. and distributed globally by Saif Pharma, plays a crucial role in the management of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.
As a cornerstone of modern lung cancer treatment protocols, Pemetor 100 mg provides oncologists with a sophisticated therapeutic tool supported by extensive clinical evidence. Its strategic incorporation into both combination and single-agent treatment regimens has contributed to improved survival outcomes and disease management for patients with these challenging malignancies across the world.
Therapeutic Indications
Pemetor 100 mg (Pemetrexed) Injection is specifically indicated for multiple clinical scenarios in the management of non-squamous NSCLC and mesothelioma:
Non-Small Cell Lung Cancer (NSCLC)
- Initial Treatment: For patients with locally advanced or metastatic, non-squamous NSCLC in combination with cisplatin as first-line therapy
- Maintenance Treatment: As a single agent for patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy
- Recurrent Disease: As a single agent for patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy
Malignant Pleural Mesothelioma
- In combination with cisplatin for patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery
These specific indications reflect the robust clinical evidence supporting pemetrexed’s efficacy in these challenging malignancies, making Pemetor® a vital component of evidence-based oncology practice.
Mechanism of Action
Pemetor® contains pemetrexed, a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. Its anticancer effects occur through several sophisticated mechanisms:
- Multi-Enzyme Inhibition: Pemetrexed and its polyglutamated metabolites inhibit multiple folate-dependent enzymes critical for cell division:
- Thymidylate synthase (TS)
- Dihydrofolate reductase (DHFR)
- Glycinamide ribonucleotide formyltransferase (GARFT)
- Aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT)
- Disruption of DNA Synthesis: By inhibiting these enzymes, pemetrexed prevents the formation of thymidine and purine nucleotides essential for DNA synthesis and repair.
- Selective Cancer Cell Effect: The multi-targeted nature of pemetrexed creates multiple points of intervention in cellular metabolism, potentially overcoming resistance mechanisms that might develop against single-target agents.
This distinctive mechanism makes Pemetor® particularly valuable in treating non-squamous NSCLC and mesothelioma, which often demonstrate sensitivity to antifolate therapies due to their cellular characteristics.
Pharmaceutical Formulation
Each vial of Pemetor 100 mg contains pemetrexed disodium equivalent to 100 mg pemetrexed, formulated as a sterile lyophilized powder for intravenous administration after reconstitution. The formulation is specifically designed to ensure stability, potency, and proper delivery of the active ingredient to target tissues.
The product is manufactured under stringent quality control standards by Eskayef Pharmaceuticals Ltd., a company with over three decades of pharmaceutical excellence. Founded in 1990 when Bangladesh operations of SK&F USA were acquired by the respected Transcom Group, Eskayef has established itself as a premier provider of world-class medicines.
Dosage and Administration Guidelines
Pemetor 100 mg (Pemetrexed) Injection requires administration by qualified healthcare professionals in settings equipped for chemotherapy delivery and monitoring. The recommended dosing regimens are:
For Non-Small Cell Lung Cancer
- Standard dose: 500 mg/m² administered intravenously over 10 minutes on Day 1 of each 21-day cycle
- Initial treatment: In combination with cisplatin for up to six cycles
- Maintenance treatment: As a single agent until disease progression or unacceptable toxicity
- Recurrent disease: As a single agent until disease progression or unacceptable toxicity
For Malignant Pleural Mesothelioma
- Standard dose: 500 mg/m² administered intravenously over 10 minutes on Day 1 of each 21-day cycle
- Administration: In combination with cisplatin until disease progression or unacceptable toxicity
Supportive Care Requirements
- Vitamin supplementation: Folic acid and vitamin B12 supplementation is essential to reduce treatment-related hematologic and gastrointestinal toxicity
- Corticosteroid premedication: Dexamethasone or equivalent should be administered before, during, and after Pemetor® treatment to reduce the incidence and severity of cutaneous reactions
Renal Function Considerations
- Recommended only for patients with creatinine clearance ≥45 mL/min
- Dose adjustments may be required based on hematologic and non-hematologic toxicities
Clinical Pharmacology
Pemetrexed demonstrates a predictable pharmacokinetic profile following intravenous administration. The drug is approximately at a steady state with equal distribution between systemic circulation and tissues, with limited protein binding allowing for effective tissue penetration. Pemetrexed undergoes limited hepatic metabolism and is primarily eliminated unchanged through renal excretion.
Understanding these pharmacokinetic properties helps clinicians optimize dosing strategies and monitoring protocols, particularly for patients with renal impairment or other factors that might affect drug clearance.
Safety and Tolerability Profile
As with all potent cytotoxic agents, Pemetor 100 mg can produce various adverse effects that require careful monitoring and management. Common adverse events include:
Hematological Effects
- Myelosuppression (neutropenia, thrombocytopenia, and anemia)
- Increased risk of infection and bleeding
Gastrointestinal Effects
- Nausea and vomiting
- Diarrhea or constipation
- Stomatitis and mucositis
Dermatological Effects
- Skin rash
- Potential for bullous and exfoliative skin toxicity
Pulmonary Effects
- Risk of interstitial pneumonitis
- Potential radiation recall in previously irradiated areas
Healthcare providers should implement appropriate monitoring protocols, supportive care measures, and vitamin supplementation to manage these effects while maximizing therapeutic benefits.
Important Precautions and Contraindications
Pemetor requires careful consideration of several important precautions:
Laboratory Monitoring
- Complete blood counts before each dose
- Renal and hepatic function assessment
- Adjustment or delay of therapy based on laboratory values
Contraindications
- History of severe hypersensitivity reaction to pemetrexed
- Pregnancy (Category D)
Special Populations
- Elderly patients may experience higher incidences of adverse reactions
- Not recommended for pediatric patients
- Requires careful consideration in patients with renal impairment
Global Access Through Saif Pharma
Saif Pharma, established in 2014, has developed extensive distribution networks to make Pemetor 100 mg available to healthcare facilities across more than 60 countries worldwide. As a specialized oncology medicine platform, Saif Pharma ensures consistent supply of this essential medication to major markets including:
- North America (United States and Canada)
- Middle East (Saudi Arabia, UAE)
- Asia (China, India, Pakistan)
- And numerous additional regions
This global reach reflects Saif Pharma’s commitment to expanding access to high-quality, affordable oncology medications worldwide. By maintaining reliable supply chains and competitive pricing structures, we help healthcare systems overcome barriers to providing optimal lung cancer and mesothelioma treatment.
Professional Support Resources
Healthcare providers utilizing Pemetor 100 mg Injection can access comprehensive support through Saif Pharma’s dedicated oncology resource channels. These include:
- Technical documentation covering stability, compatibility, and handling
- Educational materials addressing optimal administration techniques
- Clinical guidance on managing common adverse effects
- Consultation services for complex cases or specialized protocols
- Supply chain management solutions for institutional purchasers
These professional resources complement the physical product, creating an integrated support system that enhances treatment delivery and patient outcomes.
Storage and Stability Information
To maintain the potency and safety of Pemetor 100 mg:
- Store unopened vials at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)
- Follow institutional guidelines for reconstitution and dilution
- Administer diluted solution promptly or according to established stability guidelines
Healthcare facilities should follow these storage recommendations to ensure product stability until administration.
Conclusion
Pemetor 100 mg (Pemetrexed) Injection represents a significant advancement in targeted cancer therapy, offering healthcare providers a sophisticated therapeutic option supported by extensive clinical evidence. Manufactured by Eskayef Pharmaceuticals Ltd. and distributed globally by Saif Pharma, this premium oncology medication continues to improve outcomes for patients with non-squamous NSCLC and malignant pleural mesothelioma.
Our commitment to quality manufacturing, reliable distribution, and affordable access aligns with global efforts to enhance cancer care standards worldwide. Through strategic partnerships with healthcare providers across more than 60 countries, we contribute to better treatment outcomes and improved quality of life for patients facing these challenging malignancies.
For detailed prescribing information, technical specifications, or supply inquiries regarding Pemetor 100 mg Injection, please contact our specialized oncology team through www.saifpharma.com or visit the manufacturer’s website at www.skfbd.com.
